Stock 4507 SHIONOGI & CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Shionogi & Co., Ltd.

Equities

4507

JP3347200002

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-06-06 am EDT 		5-day change 1st Jan Change
7,235 JPY +0.37% Intraday chart for Shionogi & Co., Ltd. +3.71% +6.43%
May. 14 Japan's Nikkei drifts sideways as more earnings, US CPI awaited RE
May. 13 Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial RE

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Japan's Nikkei drifts sideways as more earnings, US CPI awaited
RE
Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial
RE
Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd
CI
Shionogi & Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024
CI
Shionogi & Co Completes Cancellation of 10.84 Million Treasury Shares
MT
Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study of Fetroja®/F etcroja® (cefiderocol)
CI
Shionogi Completes Up to 75 Billion Yen Share Buyback
MT
Tranche Update on Shionogi & Co., Ltd.'s Equity Buyback Plan announced on July 31, 2023.
CI
Final dividend
FA
Shionogi & Co., Ltd.'s Equity Buyback announced on July 31, 2023, has closed with 10,842,100 shares, representing 3.73% for ¥74,999.22 million.
CI
Shionogi Buys Back Shares Worth Nearly 12 Billion Yen
MT
GSK says ViiV's cabotegravir study supports longer HIV dose interval
AN
Shionogi & Co., Ltd. Announces Xocova Obtains Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection
CI
US urges court to preserve Obamacare mandate to cover cancer screenings, HIV drugs
RE
GSK's new HIV drug formula could support longer dosing intervals (March 4)
RE
GSK Says Data Show For First Time New Ultra Long-Acting Cabotegravir Formulation That Doubles Current Dosing Interval
RE
US court to weigh Obamacare mandate to cover HIV drug, cancer screenings
RE
PureTech notes positive results from Shionogi's EndeavorRx ADHD trial
AN
Akili, Inc. Announces Positive Results from Shionogi & Co., Ltd. Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx for Pediatric ADHD Patients in Japan
CI
Akili's Japan Partner Submits SDT-001 for Marketing Approval in Japan
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4507 Stock
  4. News Shionogi & Co., Ltd.
  5. Highlights